Comparison - GENE - NASDAQ

Weiss Ratings	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Rating	E
Reward Index	Very Weak
Risk Index	Very Weak
Risk Grade	E+
Reward Grade	E

Rating Factors	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Dividend Index	--
Growth Index	Weak
Efficiency Index	Very Weak
Solvency Index	Good
Total Return Index	Very Weak
Volatility Index	Very Weak

Beta / Standard Deviation	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Beta	0.96

Price History	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
7-Day Total Return	-22.78%
30-Day Total Return	-6.51%
60-Day Total Return	25.13%
90-Day Total Return	-18.12%
Year to Date Total Return	-5.24%
1-Year Total Return	-50.71%
2-Year Total Return	-70.08%
3-Year Total Return	-88.13%
5-Year Total Return	-85.03%
52-Week High % Change	-63.05%
52-Week Low % Change	21.11%

Price	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
52-Week High Price	$5.90
52-Week Low Price	$1.80
52-Week Low Price (Date)	Feb 26, 2024
52-Week High Price (Date)	May 23, 2023

Valuation	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Market Cap	10.38M
Enterprise Value	8.23M
Price/Earnings (TTM)	--
Earnings Per Share (TTM)	-0.07
Earnings Per Share Growth	15.25%
Price/Earnings To Growth	--
Price/Sales (TTM)	39.32
Price/Book (Q)	81.69
Enterprise Value/Revenue (TTM)	1.13
Price	$2.44
Enterprise Value/EBITDA (TTM)	-1.17
Enterprise Value/EBIT	-1.14
Market Cap Category	Nano Cap

Dividends and Shares	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Shares Outstanding	115.42M
Dividend Yield	--
Div. Per Share (Most Recent)	--
Dividend Per Share (TTM)	--
Payout Ratio (TTM)	--
Dividend Per Share (Most Recent)	--

Company Info	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Phone Number	61 3 8412 7000
Address	60-66 Hanover Street Fitzroy, VIC 3065
Website	genetype.com
Country	Australia
Year Founded	1987

Profitability	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Operating Margin (TTM)	-99.35%
Profit Margin	-123.95%

Management Effectiveness	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Return on Assets	-51.47%
Return on Equity	--

Income Statement	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Revenue (TTM)	5.65M
Total Revenue (TTM)	6.81M
Revenue Per Share	$0.06
Gross Profit (TTM)	4.19M
EBITDA (TTM)	-6.55M
EBIT (TTM)	-6.77M
Net Income (TTM)	-8.44M
Net Income Avl. to Common (TTM)	-8.44M
Total Revenue Growth (Q YOY)	-2.99%
Earnings Growth (Q YOY)	-16.50%
EPS Diluted (TTM)	-0.07
EPS Diluted Growth (Q YOY)	6.70%

Balance Sheet	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash and Short-Term Inv. (Q)	2.54M
Cash Per Share (Q)	$0.02
Total Current Assets (Q)	3.90M
Total Preferred Equity (Q)	--
Total Equity (Q)	3.28M
Current Ratio (Q)	1.670
Book Value Per Share (Q)	$0.03
Total Assets (Q)	5.77M
Total Current Liabilities (Q)	2.33M
Total Debt (Q)	260.60K
Total Liabilities (Q)	2.49M
Total Common Equity (Q)	3.28M

Cash Flow	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash from Investing (TTM)	124.80K
Cash from Financing (TTM)	4.00M
Net Change in Cash (TTM)	-796.70K
Levered Free Cash Flow (TTM)	-3.06M
Cash from Operations (TTM)	-5.05M